Time New York: Wed 28 Sep 21:40 pm  |  Save 15% on H&R Block Online


Zimmer Biomet Introduces Vanguard Individualized Design


Zimmer Biomet Holdings, Inc. ZBH, a leading player in global musculoskeletal healthcare, recently announced the launch of Vanguard Individualized Design (ID), an advanced total knee arthroplasty (TKA) system. This latest design enables the implant to be a personalized fit which simplifies soft tissue preservation and balance.

Traditional total knee implants had a one-piece bearing of polyethylene placed between the metal portions. Vanguard ID is the only TKA system to include two individual polyethylene bearings with different articulations on the medial and lateral sides.

We note that Vanguard ID differs from its earlier versions of knee replacement products as well. The original Vanguard Knee system introduced in 2003 allowed personalization in knee replacement by offering a wide range of available sizes.



Management at Zimmer Biomet feels that Vanguard ID will transform the total knee replacement process. While simplifying the surgical process of knee implants, this system will help surgeons to achieve higher patient satisfaction.

As per a Medgadget report, the global knee implant market is forecasted to reach a worth of $15 billion in 2018, at a CAGR of 8.64% during 2011–2018. The knee implants market is benefitting from the rise in the rate of age-related diseases like osteoporosis, arthritis, diabetes, obesity, ageing population and injuries related to sports. Accordingly, we expect a huge uptake of the latest Vanguard product.

Notably, Zimmer Biomet has exhibited positive numbers in its knee implant portfolio in the recently concluded second quarter. It has recorded a 5% sales growth in the knee category. The company has a constant urge to develop quality knee-replacement solutions so that it can capture a larger share of the growing knee arthroplasty market.

Zacks Rank & Key Picks

Zimmer Biomet currently has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical product sector are GW Pharmaceuticals plc GWPH, NuVasive, Inc. NUVA and Quidel Corp. QDEL. All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.